Ysios Capital’s portfolio company Adcendo announces extension of Series A financing to 82M€ to ensure broad development of first-in-class ADC pipeline 

04/04/2023 Nota de prensa YSIOS CAPITAL’S PORTFOLIO COMPANY ADCENDO ANNOUNCES EXTENSION OF SERIES A FINANCING TO 82M€ TO ENSURE BROAD DEVELOPMENT OF FIRST-IN-CLASS ADC PIPELINE Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful…

Ysios Capital’s portfolio company Adcendo appoints Michael Pehl as Chief Executive Officer 

07/07/2021 Nota de prensa YSIOS CAPITAL´S PORTFOLIO COMPANY ADCENDO APPOINTS MICHAEL PEHL AS CHIEF EXECUTIVE OFFICER. Adcendo, a biotech company developing innovative antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces today the appointment of Michael Pehl as Chief Executive Officer (CEO). Henrik Stage, co-founder of Adcendo, will move to the role of Chief…

Ysios Capital lidera una inversión de €51 millones en Adcendo. Acuden también Novo Seeds, RA Capital Management, HealthCap y Gilde

29/04/2021 Nota de prensa YSIOS CAPITAL LIDERA UNA INVERSIÓN DE €51 MILLONES EN ADCENDO.                   − Adcendo (Copenhague, Dinamarca), es una compañía biotecnológica especializada en el desarrollo de fármacos inmunoconjugados para el tratamiento de ciertos tipos de cáncer que no responden a las terapias actuales. − Ysios…